Crossmark

Vinorelbine plus Capecitabine (Vinocap): a retrospective analysis in heavily pretreated HER2 negative metastatic breast cancer patients

Crossref DOI link: https://doi.org/10.1007/s10549-019-05203-1

Published Online: 2019-03-21

Published Print: 2019-07

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Torres, Alfredo

Ramdial, Jeremy L.

Aguirre, Luis E. https://orcid.org/0000-0002-5377-9252
Mahtani, Reshma

Vogel, Charles L.
License Information

Text and Data Mining valid from 2019-03-21
More Information

Article History

Received: 5 March 2019

Accepted: 13 March 2019

First Online: 21 March 2019

Compliance with ethical standards

:

: Reshma Mahtani serves as consultant for Pfizer, Lilly, Novartis, Amgen, Celgene, Eisai, Agendia, PUMA biotechnology and Biotherapeutics Inc. Charles L. Vogel serves as consultant/advisor for PUMA biotechnology and ADGERO biopharmaceuticals. Alfredo Torres, Jeremy L. Ramdial and Luis E. Aguirre declare that they have no conflict of interest. The authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest, or non-financial in the subject matter or materials discussed in this manuscript.

: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

: Informed consent was obtained from all individual participants included in the study.